Compare Roblox Corp (RBLX) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roblox Corp vs Regeneron Pharmaceuticals Inc — how do they compare? Roblox Corp trades at $49.61 (market cap $37.59B), while Regeneron Pharmaceuticals Inc trades at $653.5 (market cap $70.79B). The key difference: Regeneron Pharmaceuticals Inc is the larger of the two by market cap, and Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Roblox Corp pays none. Which is the better fit depends on your goals.
| RBLX | REGN | |
|---|---|---|
Market Cap | $37.59B | $70.79B |
Sector | Media | Health |
52-Week High | $141.56 | $812.27 |
52-Week Low | $41.30 | $545.46 |
Enterprise Value | $36.18B | $64.74B |
Dividend Yield | — | 0.56% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Roblox Corp
Roblox operates an online video game platform that lets young gamers create, develop, and monetize games (or experiences) for other players. The firm effectively offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning revenue in multiple places while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers then creating new games or franchises. Roblox is increasingly focused on creating a metaverse that moves beyond games toward experiences like concerts, education, and even business management.
Read more on RBLX →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
